A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors

Clinical Trial ID NCT02221960

Rank	Title	Journal	Year	PubWeight™‹?›
1	PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.	Sci Transl Med	2016	2.16
2	The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.	Nat Rev Clin Oncol	2016	2.09
3	OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.	Front Oncol	2015	1.01
4	PD-1/PD-L1 blockade in cancer treatment: perspectives and issues.	Int J Clin Oncol	2016	0.95
5	Roles of regulatory T cells in cancer immunity.	Int Immunol	2016	0.95
6	New strategies in immunotherapy for non-small cell lung cancer.	Transl Lung Cancer Res	2015	0.89
7	Advances in immunotherapy for melanoma.	BMC Med	2016	0.83
8	Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.	Immunotherapy	2015	0.81
9	Advances in targeted and immunobased therapies for colorectal cancer in the genomic era.	Onco Targets Ther	2016	0.81
10	Emerging therapeutic targets in metastatic progression: A focus on breast cancer.	Pharmacol Ther	2016	0.79
11	Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect.	J Immunol Res	2015	0.78
12	Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond.	Ther Adv Med Oncol	2016	0.77
13	Antibody-based immunotherapy of solid cancers: progress and possibilities.	Immunotherapy	2015	0.77
14	Future perspectives in cancer immunotherapy.	Ann Transl Med	2016	0.77